XSHE002755
Market cap1.58bUSD
Jan 15, Last price
12.46CNY
1D
-2.12%
1Q
-8.92%
Jan 2017
-44.84%
IPO
88.02%
Name
Beijing Aosaikang Pharmaceutical Co Ltd
Chart & Performance
P/E
—
P/S
8.01
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.28%
Rev. gr., 5y
-18.16%
Revenues
1.44b
-22.92%
Net income
-149m
CFO
-27m
Dividend
Jun 20, 20220.1 CNY/sh
Earnings
May 29, 2025
Profile
Beijing Aosaikang Pharmaceutical Co., Ltd. researches, develops, manufactures, markets, and sells pharmaceuticals, fine chemicals, and health-care products in China. It offers proton pump inhibitor injections and oncology medicines, as well as APIs. The company provides its products in digestive, oncology, antibiotic, and other areas. Beijing Aosaikang Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 1,443,460 -22.92% | 1,872,572 -39.72% | |||||||
Cost of revenue | 1,622,923 | 2,072,328 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (179,464) | (199,756) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 6,550 | 3,701 | |||||||
Tax Rate | |||||||||
NOPAT | (186,014) | (203,457) | |||||||
Net income | (148,530) | ||||||||
Dividends | (92,816) | ||||||||
Dividend yield | 1.26% | ||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 114,019 | 48,487 | |||||||
Long-term debt | 13,508 | 17,837 | |||||||
Deferred revenue | 64,720 | 55,808 | |||||||
Other long-term liabilities | 2 | 1 | |||||||
Net debt | (1,037,731) | (1,545,467) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (26,568) | ||||||||
CAPEX | (129,319) | ||||||||
Cash from investing activities | 11,563 | ||||||||
Cash from financing activities | 291,174 | 75,912 | |||||||
FCF | 12,179 | 56,695 | |||||||
| Balance | |||||||||
Cash | 1,760,873 | 1,611,791 | |||||||
Long term investments | (595,616) | ||||||||
Excess cash | 1,093,085 | 1,518,162 | |||||||
Stockholders' equity | 2,625,515 | 2,965,719 | |||||||
Invested Capital | 2,103,091 | 1,593,627 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 928,311 | 928,160 | |||||||
Price | 10.82 36.27% | 7.94 -36.98% | |||||||
Market cap | 10,044,325 36.29% | 7,369,593 -36.98% | |||||||
EV | 9,117,291 | 5,874,496 | |||||||
EBITDA | (94,763) | (107,564) | |||||||
EV/EBITDA | |||||||||
Interest | 3,080 | 2,764 | |||||||
Interest/NOPBT | |||||||||